The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Breast Cancer Liquid Biopsy-Global Market Insights and Sales Trends 2024
Synopsis
Breast Cancer Liquid Biopsy can be usually used in breast biopsy, based on circulating biomarkers, the market is categorized into circulating tumor cells (CTCs), cell-free DNA (cfDNA), extracellular vesicles (EVs), and other circulating biomarkers.
The global Breast Cancer Liquid Biopsy market size is expected to reach US$ 1006 million by 2029, growing at a CAGR of 17.4% from 2023 to 2029. The market is mainly driven by the significant applications of Breast Cancer Liquid Biopsy in various end use industries. The expanding demands from the Hospitals, Diagnostic Centers and Laboratories,, are propelling Breast Cancer Liquid Biopsy market. Circulating Tumor Cells (CTCs), one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the Cell-Free DNA (CfDNA) segment is estimated at % CAGR for the next seven-year period.
Asia Pacific shows high growth potential for Breast Cancer Liquid Biopsy market, driven by demand from China, the second largest economy with some signs of stabilising, the Breast Cancer Liquid Biopsy market in China is forecast to reach US$ million by 2029, trailing a CAGR of % over the 2023-2029 period, while the U.S. market will reach US$ million by 2029, exhibiting a CAGR of % during the same period.
Report Objectives
This report provides market insight on the different segments, by players, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Breast Cancer Liquid Biopsy, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global Breast Cancer Liquid Biopsy market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global Breast Cancer Liquid Biopsy market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Breast Cancer Liquid Biopsy sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Breast Cancer Liquid Biopsy covered in this report include QIAGEN, Roche Diagnostics, Bio-Rad Laboratories, Myriad Genetics, Menarini Silicon Biosystems, Genomic Health, Thermo Fisher Scientific, Illumina and Biocept, etc.
The global Breast Cancer Liquid Biopsy market report caters to various stakeholders in this industry including investors, suppliers, product players, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
QIAGEN
Roche Diagnostics
Bio-Rad Laboratories
Myriad Genetics
Menarini Silicon Biosystems
Genomic Health
Thermo Fisher Scientific
Illumina
Biocept
Trovagene
Guardant Health
RainDance Technologies
MDx Health
Global Breast Cancer Liquid Biopsy market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Breast Cancer Liquid Biopsy market, Segment by Type:
Circulating Tumor Cells (CTCs)
Cell-Free DNA (CfDNA)
Extracellular Vesicles (EVs)
Other Circulating Biomarkers
Global Breast Cancer Liquid Biopsy market, by Application
Hospitals
Diagnostic Centers
Laboratories
Core Chapters
Chapter One: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2018-2023, 2024-2029). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter Two: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter Three: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter Four: Detailed analysis of Breast Cancer Liquid Biopsy companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Five: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter Six, Seven, Eight, Nine and Ten: North America, Europe, Asia Pacific, Latin America, Middle East & Africa, revenue by country.
Chapter Eleven: this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Research Finding/Conclusion
Breast Cancer Liquid Biopsy can be usually used in breast biopsy, based on circulating biomarkers, the market is categorized into circulating tumor cells (CTCs), cell-free DNA (cfDNA), extracellular vesicles (EVs), and other circulating biomarkers.
The global Breast Cancer Liquid Biopsy market size is expected to reach US$ 1006 million by 2029, growing at a CAGR of 17.4% from 2023 to 2029. The market is mainly driven by the significant applications of Breast Cancer Liquid Biopsy in various end use industries. The expanding demands from the Hospitals, Diagnostic Centers and Laboratories,, are propelling Breast Cancer Liquid Biopsy market. Circulating Tumor Cells (CTCs), one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the Cell-Free DNA (CfDNA) segment is estimated at % CAGR for the next seven-year period.
Asia Pacific shows high growth potential for Breast Cancer Liquid Biopsy market, driven by demand from China, the second largest economy with some signs of stabilising, the Breast Cancer Liquid Biopsy market in China is forecast to reach US$ million by 2029, trailing a CAGR of % over the 2023-2029 period, while the U.S. market will reach US$ million by 2029, exhibiting a CAGR of % during the same period.
Report Objectives
This report provides market insight on the different segments, by players, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Breast Cancer Liquid Biopsy, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global Breast Cancer Liquid Biopsy market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global Breast Cancer Liquid Biopsy market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Breast Cancer Liquid Biopsy sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Breast Cancer Liquid Biopsy covered in this report include QIAGEN, Roche Diagnostics, Bio-Rad Laboratories, Myriad Genetics, Menarini Silicon Biosystems, Genomic Health, Thermo Fisher Scientific, Illumina and Biocept, etc.
The global Breast Cancer Liquid Biopsy market report caters to various stakeholders in this industry including investors, suppliers, product players, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
QIAGEN
Roche Diagnostics
Bio-Rad Laboratories
Myriad Genetics
Menarini Silicon Biosystems
Genomic Health
Thermo Fisher Scientific
Illumina
Biocept
Trovagene
Guardant Health
RainDance Technologies
MDx Health
Global Breast Cancer Liquid Biopsy market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Breast Cancer Liquid Biopsy market, Segment by Type:
Circulating Tumor Cells (CTCs)
Cell-Free DNA (CfDNA)
Extracellular Vesicles (EVs)
Other Circulating Biomarkers
Global Breast Cancer Liquid Biopsy market, by Application
Hospitals
Diagnostic Centers
Laboratories
Core Chapters
Chapter One: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2018-2023, 2024-2029). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter Two: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter Three: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter Four: Detailed analysis of Breast Cancer Liquid Biopsy companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Five: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter Six, Seven, Eight, Nine and Ten: North America, Europe, Asia Pacific, Latin America, Middle East & Africa, revenue by country.
Chapter Eleven: this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Research Finding/Conclusion
Index1 Market Overview of Breast Cancer Liquid Biopsy
1.1 Breast Cancer Liquid Biopsy Market Overview
1.1.1 Breast Cancer Liquid Biopsy Product Scope
1.1.2 Breast Cancer Liquid Biopsy Market Status and Outlook
1.2 Global Breast Cancer Liquid Biopsy Market Size Overview by Region 2018 VS 2022 VS 2029
1.3 Global Breast Cancer Liquid Biopsy Market Size by Region (2018-2029)
1.4 Global Breast Cancer Liquid Biopsy Historic Market Size by Region (2018-2023)
1.5 Global Breast Cancer Liquid Biopsy Market Size Forecast by Region (2024-2029)
1.6 Key Regions, Breast Cancer Liquid Biopsy Market Size (2018-2029)
1.6.1 North America Breast Cancer Liquid Biopsy Market Size (2018-2029)
1.6.2 Europe Breast Cancer Liquid Biopsy Market Size (2018-2029)
1.6.3 Asia-Pacific Breast Cancer Liquid Biopsy Market Size (2018-2029)
1.6.4 Latin America Breast Cancer Liquid Biopsy Market Size (2018-2029)
1.6.5 Middle East & Africa Breast Cancer Liquid Biopsy Market Size (2018-2029)
2 Breast Cancer Liquid Biopsy Market by Type
2.1 Introduction
2.1.1 Circulating Tumor Cells (CTCs)
2.1.2 Cell-Free DNA (CfDNA)
2.1.3 Extracellular Vesicles (EVs)
2.1.4 Other Circulating Biomarkers
2.2 Global Breast Cancer Liquid Biopsy Market Size by Type: 2018 VS 2022 VS 2029
2.2.1 Global Breast Cancer Liquid Biopsy Historic Market Size by Type (2018-2023)
2.2.2 Global Breast Cancer Liquid Biopsy Forecasted Market Size by Type (2024-2029)
2.3 Key Regions Market Size by Type
2.3.1 North America Breast Cancer Liquid Biopsy Revenue Breakdown by Type (2018-2029)
2.3.2 Europe Breast Cancer Liquid Biopsy Revenue Breakdown by Type (2018-2029)
2.3.3 Asia-Pacific Breast Cancer Liquid Biopsy Revenue Breakdown by Type (2018-2029)
2.3.4 Latin America Breast Cancer Liquid Biopsy Revenue Breakdown by Type (2018-2029)
2.3.5 Middle East and Africa Breast Cancer Liquid Biopsy Revenue Breakdown by Type (2018-2029)
3 Breast Cancer Liquid Biopsy Market Overview by Application
3.1 Introduction
3.1.1 Hospitals
3.1.2 Diagnostic Centers
3.1.3 Laboratories
3.2 Global Breast Cancer Liquid Biopsy Market Size by Application: 2018 VS 2022 VS 2029
3.2.1 Global Breast Cancer Liquid Biopsy Historic Market Size by Application (2018-2023)
3.2.2 Global Breast Cancer Liquid Biopsy Forecasted Market Size by Application (2024-2029)
3.3 Key Regions Market Size by Application
3.3.1 North America Breast Cancer Liquid Biopsy Revenue Breakdown by Application (2018-2029)
3.3.2 Europe Breast Cancer Liquid Biopsy Revenue Breakdown by Application (2018-2029)
3.3.3 Asia-Pacific Breast Cancer Liquid Biopsy Revenue Breakdown by Application (2018-2029)
3.3.4 Latin America Breast Cancer Liquid Biopsy Revenue Breakdown by Application (2018-2029)
3.3.5 Middle East and Africa Breast Cancer Liquid Biopsy Revenue Breakdown by Application (2018-2029)
4 Breast Cancer Liquid Biopsy Competition Analysis by Players
4.1 Global Breast Cancer Liquid Biopsy Market Size by Players (2018-2023)
4.2 Global Top Players by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Breast Cancer Liquid Biopsy as of 2022)
4.3 Date of Key Players Enter into Breast Cancer Liquid Biopsy Market
4.4 Global Top Players Breast Cancer Liquid Biopsy Headquarters and Area Served
4.5 Key Players Breast Cancer Liquid Biopsy Product Solution and Service
4.6 Competitive Status
4.6.1 Breast Cancer Liquid Biopsy Market Concentration Rate
4.6.2 Mergers & Acquisitions, Expansion Plans
5 Company (Top Players) Profiles
5.1 QIAGEN
5.1.1 QIAGEN Profile
5.1.2 QIAGEN Main Business
5.1.3 QIAGEN Breast Cancer Liquid Biopsy Products, Services and Solutions
5.1.4 QIAGEN Breast Cancer Liquid Biopsy Revenue (US$ Million) & (2018-2023)
5.1.5 QIAGEN Recent Developments
5.2 Roche Diagnostics
5.2.1 Roche Diagnostics Profile
5.2.2 Roche Diagnostics Main Business
5.2.3 Roche Diagnostics Breast Cancer Liquid Biopsy Products, Services and Solutions
5.2.4 Roche Diagnostics Breast Cancer Liquid Biopsy Revenue (US$ Million) & (2018-2023)
5.2.5 Roche Diagnostics Recent Developments
5.3 Bio-Rad Laboratories
5.3.1 Bio-Rad Laboratories Profile
5.3.2 Bio-Rad Laboratories Main Business
5.3.3 Bio-Rad Laboratories Breast Cancer Liquid Biopsy Products, Services and Solutions
5.3.4 Bio-Rad Laboratories Breast Cancer Liquid Biopsy Revenue (US$ Million) & (2018-2023)
5.3.5 Myriad Genetics Recent Developments
5.4 Myriad Genetics
5.4.1 Myriad Genetics Profile
5.4.2 Myriad Genetics Main Business
5.4.3 Myriad Genetics Breast Cancer Liquid Biopsy Products, Services and Solutions
5.4.4 Myriad Genetics Breast Cancer Liquid Biopsy Revenue (US$ Million) & (2018-2023)
5.4.5 Myriad Genetics Recent Developments
5.5 Menarini Silicon Biosystems
5.5.1 Menarini Silicon Biosystems Profile
5.5.2 Menarini Silicon Biosystems Main Business
5.5.3 Menarini Silicon Biosystems Breast Cancer Liquid Biopsy Products, Services and Solutions
5.5.4 Menarini Silicon Biosystems Breast Cancer Liquid Biopsy Revenue (US$ Million) & (2018-2023)
5.5.5 Menarini Silicon Biosystems Recent Developments
5.6 Genomic Health
5.6.1 Genomic Health Profile
5.6.2 Genomic Health Main Business
5.6.3 Genomic Health Breast Cancer Liquid Biopsy Products, Services and Solutions
5.6.4 Genomic Health Breast Cancer Liquid Biopsy Revenue (US$ Million) & (2018-2023)
5.6.5 Genomic Health Recent Developments
5.7 Thermo Fisher Scientific
5.7.1 Thermo Fisher Scientific Profile
5.7.2 Thermo Fisher Scientific Main Business
5.7.3 Thermo Fisher Scientific Breast Cancer Liquid Biopsy Products, Services and Solutions
5.7.4 Thermo Fisher Scientific Breast Cancer Liquid Biopsy Revenue (US$ Million) & (2018-2023)
5.7.5 Thermo Fisher Scientific Recent Developments
5.8 Illumina
5.8.1 Illumina Profile
5.8.2 Illumina Main Business
5.8.3 Illumina Breast Cancer Liquid Biopsy Products, Services and Solutions
5.8.4 Illumina Breast Cancer Liquid Biopsy Revenue (US$ Million) & (2018-2023)
5.8.5 Illumina Recent Developments
5.9 Biocept
5.9.1 Biocept Profile
5.9.2 Biocept Main Business
5.9.3 Biocept Breast Cancer Liquid Biopsy Products, Services and Solutions
5.9.4 Biocept Breast Cancer Liquid Biopsy Revenue (US$ Million) & (2018-2023)
5.9.5 Biocept Recent Developments
5.10 Trovagene
5.10.1 Trovagene Profile
5.10.2 Trovagene Main Business
5.10.3 Trovagene Breast Cancer Liquid Biopsy Products, Services and Solutions
5.10.4 Trovagene Breast Cancer Liquid Biopsy Revenue (US$ Million) & (2018-2023)
5.10.5 Trovagene Recent Developments
5.11 Guardant Health
5.11.1 Guardant Health Profile
5.11.2 Guardant Health Main Business
5.11.3 Guardant Health Breast Cancer Liquid Biopsy Products, Services and Solutions
5.11.4 Guardant Health Breast Cancer Liquid Biopsy Revenue (US$ Million) & (2018-2023)
5.11.5 Guardant Health Recent Developments
5.12 RainDance Technologies
5.12.1 RainDance Technologies Profile
5.12.2 RainDance Technologies Main Business
5.12.3 RainDance Technologies Breast Cancer Liquid Biopsy Products, Services and Solutions
5.12.4 RainDance Technologies Breast Cancer Liquid Biopsy Revenue (US$ Million) & (2018-2023)
5.12.5 RainDance Technologies Recent Developments
5.13 MDx Health
5.13.1 MDx Health Profile
5.13.2 MDx Health Main Business
5.13.3 MDx Health Breast Cancer Liquid Biopsy Products, Services and Solutions
5.13.4 MDx Health Breast Cancer Liquid Biopsy Revenue (US$ Million) & (2018-2023)
5.13.5 MDx Health Recent Developments
6 North America
6.1 North America Breast Cancer Liquid Biopsy Market Size by Country (2018-2029)
6.2 U.S.
6.3 Canada
7 Europe
7.1 Europe Breast Cancer Liquid Biopsy Market Size by Country (2018-2029)
7.2 Germany
7.3 France
7.4 U.K.
7.5 Italy
7.6 Russia
7.7 Nordic Countries
7.8 Rest of Europe
8 Asia-Pacific
8.1 Asia-Pacific Breast Cancer Liquid Biopsy Market Size by Region (2018-2029)
8.2 China
8.3 Japan
8.4 South Korea
8.5 Southeast Asia
8.6 India
8.7 Australia
8.8 Rest of Asia-Pacific
9 Latin America
9.1 Latin America Breast Cancer Liquid Biopsy Market Size by Country (2018-2029)
9.2 Mexico
9.3 Brazil
9.4 Rest of Latin America
10 Middle East & Africa
10.1 Middle East & Africa Breast Cancer Liquid Biopsy Market Size by Country (2018-2029)
10.2 Turkey
10.3 Saudi Arabia
10.4 UAE
10.5 Rest of Middle East & Africa
11 Breast Cancer Liquid Biopsy Market Dynamics
11.1 Breast Cancer Liquid Biopsy Industry Trends
11.2 Breast Cancer Liquid Biopsy Market Drivers
11.3 Breast Cancer Liquid Biopsy Market Challenges
11.4 Breast Cancer Liquid Biopsy Market Restraints
12 Research Finding /Conclusion
13 Methodology and Data Source
13.1 Methodology/Research Approach
13.1.1 Research Programs/Design
13.1.2 Market Size Estimation
13.1.3 Market Breakdown and Data Triangulation
13.2 Data Source
13.2.1 Secondary Sources
13.2.2 Primary Sources
13.3 Disclaimer
13.4 Author List
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
